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Abstract We have shown that in an estrogen receptor-negative 
multidrug-resistant subline of MCF-7 human breast carcinoma 
cells longer-term (24 h), but not shorter-term (30 min), 
treatments with clinically relevant (2-5 μΜ) concentrations of 
tamoxifen (TAM) inhibited phorbol ester-stimulated phospho-
lipase D (PLD) activity by 50-80%. TAM caused these 
inhibitory effects without inducing membrane translocation or 
down-regulation of protein kinase C-α, the major mediator of 
phorbol ester effects on PLD activation. The results raise the 
possibility that prolonged inhibition of the protein kinase C-ot-
regulated PLD system may contribute to the cytotoxic effects of 
tamoxifen in estrogen receptor-negative breast cancer cells. 
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1. Introduction 
Tamoxifen (TAM), a non-steroidal anti-estrogen, has been 
used widely and effectively to treat hormone-responsive breast 
cancer [1-3]. In cell culture studies, the inhibitory effects of 
TAM on cell growth can involve both estrogen receptor (ER)-
dependent and ER-independent components. Generally, doses 
of TAM below 1 μΜ are cytostatic reflecting inhibition of ER 
function, while 1-10 μΜ concentrations of TAM seem to in-
duce cytotoxicity independently of the ER status [4,5]. In both 
ER-positive and -negative cells induction of apoptosis may be 
responsible for the cytotoxic effects of TAM [6,7]. 
Since ER-independent inhibition of cell growth can be 
achieved by clinically relevant concentrations of TAM, this 
drug might also have beneficial effects in patients with ER-
negative tumors [8]. For this reason, it would be important to 
determine the mechanism(s) involved in the cytotoxic effects 
of TAM in ER-negative breast cancer cells. 
Human breast tumors contain elevated levels of protein 
kinase C (PKC) activity [9]. Activation of PKC by phorbol 
12-myristate 13-acetate (PMA) or 1,2-diacylglycerol can lead 
to increased phospholipase D (PLD)-mediated hydrolysis of 
phosphatidylcholine (PtdCho) and/or phosphatidylethanol-
amine (PtdEtn) (reviewed in [10]). In breast cancer cells the 
major regulator of PtdEtn hydrolysis is PKC-oc, while stimu-
lation of PtdCho hydrolysis by PMA may involve both PKC-
oc and PKC-βΙ [11]. The PKC-regulated PLD system is likely 
to be an important component of the signal transduction sys-
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tern [10]. Since higher concentrations of TAM have been 
shown to inhibit PKC activity in vitro [12-14], we examined 
possible inhibition of PMA-stimulated PLD activity by TAM. 
For this purpose, an ER-negative multidrug-resistant subline 
of MCF-7 human breast carcinoma cells (MCF-7/MDR cells) 
and NIH 3T3 fibroblasts were chosen, because in these cells 
PLD activity is well characterized [15,16], including the short-
term stimulatory effects of TAM on PtdEtn and PtdCho hy-
drolysis [17]. The results show that longer-term (24 h), but not 
shorter-term (30 min), treatments with TAM inhibit PMA-
induced PLD activity. 
2. Materials and methods 
2.1. Materials 
TAM, PMA and Dowex-50W(H+) were purchased from Sigma; [2-
14C]ethanolamine (55 mCi/mmol) and [methyl-14C]choline (55 mCi/ 
mmol) were bought from Amersham; tissue culture reagents were 
purchased from Gibco-BRL; and the polyclonal antibody raised 
against PKC-α was kindly provided by Dr. Yusuf A. Hannun 
(Duke University, Durham, NC, USA). 
2.2. Cell culture 
MCF-7/MDR cells, generously provided by Dr. Kenneth Cowan 
(National Cancer Institute, NIH, Bethesda, MD, USA), were main-
tained in Richter's modified Eagle medium supplemented with 2 mM 
glutamine, 12 mg/ml L-proline, 50 μg/ml gentamicin and 10% fetal 
bovine serum. NIH 3T3 clone 7 fibroblasts, obtained from Dr. Doug-
las R. Lowy (National Cancer Institute, NIH, Bethesda, MD, USA), 
were cultured in Dulbecco's modified Eagle medium supplemented 
with 10% fetal calf serum, penicillin (50 U/ml), streptomycin (50 μg/ 
ml) and glutamine (2 mM). 
2.3. Western blot analysis of PKC-a 
MCF-7/MDR cells in 60 mm diameter dishes were incubated in the 
absence or presence of 5-25 μΜ TAM or 100-300 nM PMA for 20 
min or 24 h. Then the cells were rapidly scraped into 1.5 ml homo-
genization buffer containing 20 mM Tris-HCl pH 7.5, 1 mM phenyl-
methylsulfonyl fluoride, 100 μg/ml leupeptin and 25 μg/ml aprotinin. 
After homogenization, homogenates were centrifuged at 15000Xg for 
20 min to prepare cytosolic and particulate fractions. The fractions 
(35^10 μg protein each) were subjected to SDS-PAGE (10% acryl-
amide minigel) and proteins were transblotted from gels to nitrocel-
lulose membranes. The membranes were reacted with polyclonal anti-
body to PKC-α (used at 1:1000 dilution), and the immunoreactive 
proteins were stained and analyzed as described earlier [18]. 
2.4. Determination of PLD-mediated formation of [uC]ethanolamine 
and [u Cjcholine from prelabeled phospholipids 
MCF-7/MDR cells or NIH 3T3 fibroblasts, grown in 12-well plates, 
were labeled with [14C]ethanolamine (0.4 μθ/ιηΐ) or [14C]choline (0.6 
μα/ηιΐ) for 48 h; when appropriate, 2-5 μΜ TAM or 300 nM PMA 
was present during the last 21 h of the incubation period. At the end 
of the labeling period the cell cultures were confluent. The cells were 
washed and then incubated for 3 h in fresh medium to complete 
incorporation of remaining radioactive precursors into cellular phos-
pholipids; when appropriate, TAM or PMA was added back to the 
medium to complete the 24 h treatment schedule. Then washed cells 
were treated with PMA or TAM for 30 min or 90 min in the presence 
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Fig. 1. Combined stimulatory effects of TAM and PMA on PtdEtn 
hydrolysis in MCF-7/MDR cells. Cells were labeled with 
[14C]ethanolamine for 48 h, and were untreated (I) or treated (II) 
with 300 nM PMA for the last 24 h of the labeling period. Washed 
cells were incubated for 30 min in the absence (empty columns) or 
presence of 25 μΜ TAM (hatched columns), 100 nM PMA (cross-
hatched columns), or TAM plus PMA (black columns). The 14C 
content of PtdEtn was 166000 dpm/well. Data represent the 
mean±S.E.M. of eight incubations performed in two separate ex-
periments with the same passage of cells. Similar results were ob-
tained in a third experiment performed in quadruplicate. 
Fig. 2. Western blot analysis of the shorter-term and longer-term ef-
fects of PMA on the cellular status of PKC-cc. MCF-7/MDR cells 
were untreated (lanes 1, 2) or were treated with 100 nM PMA for 
20 min (lanes 3, 4), or with 300 nM PMA for 24 h (lanes 5, 6). 
Lane I represents PKC-α standard from rat brain shown by the ar-
row. Lanes 1, 3, 5 were loaded with 40 μg of soluble fraction pro-
tein and lanes 2, 4, 6 were loaded with 40 μg of particulate fraction 
protein. This experiment was repeated twice with similar results. 
PMA (100 nM) on the formation of [14C]ethanolamine were 
additive. 
Although the above data suggested that the stimulatory 
effect of TAM on PLD activity was not mediated by PKC-
cc, we examined this issue further. As shown in Fig. 2, a 
treatment with 100 nM PMA for 20 min caused membrane 
translocation of PKC-α, while a treatment with 300 nM PMA 
for 24 h decreased the cellular content of this isozyme about 
75%. (A similar chronic treatment with 100 nM PMA caused 
less reduction in cellular PKC-oc.) A prolonged treatment with 
300 nM PMA slightly enhanced PLD activity, but PLD activ-
ity was not further enhanced by newly added PMA. These 
observations probably reflect that the remaining cellular 
pool of PKC-oc after chronic PMA treatment was fully acti-
vated and functional with respect to its ability to activate 
PLD. Most importantly, the stimulatory effect of TAM on 
of 2 mM ethanolamine or 20 mM choline, as appropriate, to prevent 
metabolism of radiolabeled products. Incubations were terminated by 
scraping the cells into 2 ml ice-cold methanol, followed by rapid 
transfer of the methanol extract to 2 ml of chloroform. After phase 
separation, [14C]ethanolamine, [14C]choline, and their metabolites 
were separated on Dowex-50W(H+)-packed columns as described ear-
lier [19]. 
3. Results and discussion 
The first goal was to determine the possible role of PKC in 
the short-term stimulatory effects of TAM on PLD activity 
[17]. Since in an ER-negative breast cancer cell line TAM was 
shown to increase the activity of an unspecified calcium-de-
pendent PKC isozyme(s) [20], stimulation of PLD by TAM 
could be mediated by PKC. However, TAM also was shown 
to inhibit the activity of calcium-dependent PKC isozyme(s) in 
vitro [12-14]; thus, in principle, TAM could also inhibit 
PMA-induced activation of PLD. Finally, if PKC-oc, a major 
regulator of PLD in breast cancer cells and fibroblasts [11], is 
neither stimulated nor inhibited by TAM, then TAM would 
not be expected to modulate stimulation of PLD activity by 
PMA. With these options in mind, first we determined the 
combined short-term effects of TAM and PMA on PLD ac-
tivity in MCF-7/MDR cells. In these cells, activated PLD 
hydrolyzes mainly PtdEtn [16]. This specific PLD activity 
can be determined in [14C]ethanolamine-labeled cells where 
PMA- or TAM-induced formation of [14C]ethanolamine 
from the prelabeled cellular pool of PtdEtn occurs by a 
PLD-mediated mechanism [15-17]. As shown in Fig. 1-1, in 
[14C]ethanolamine-labeled MCF-7/MDR cells the effects of 
maximally effective concentrations of TAM (25 μΜ) and 
CD 
c 
'£ 
CO 
o 
c CO 
.c 
-·—' CD 
1—' 
o i 
*4— 
o c 
o 
"■!—· 
CO 
E 1— 
o 
c 
Έ 
o 
σ> 
CD 
5 
-^ CO 
Ό 
X 
E 
O 
T3 
100 nM] 
Fig. 3. Longer-term treatments with TAM inhibit PMA-stimulated 
hydrolysis of PtdEtn in MCF-7/MDR cells. Cells were labeled with 
[14C]ethanolamine for 48 h, and were untreated (·) or treated with 
2 μΜ TAM ( A ) , or 5 μΜ TAM (■) for the last 24 h of the label-
ing period. Washed cells were incubated, in the absence of TAM, 
with 0-100 nM concentrations of PMA for 90 min. Each point rep-
resents the mean ± S.E.M of eight incubations performed in two sep-
arate experiments with the same passage of cells. Similar results 
were obtained in two other experiments each performed in tripli-
cate. 
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PtdEtn hydrolysis was not affected by the down-regulation of 
a major fraction of cellular PKC-α (Fig. l-II). In NIH 3T3 
fibroblasts as well, TAM (25 μΜ) and PMA (100 nM) had 
additive effects on the hydrolysis of both PtdCho and PtdEtn, 
and down-regulation of PKC-oc by chronic (24 h) treatment 
with 300 nM PMA failed to modify the stimulatory effects of 
TAM on these PLD activities (data not shown). These data 
indicated that short-term use of TAM does not prevent reg-
ulation of PLD by PKC-oc, and that the transient stimulatory 
effect of TAM on PLD activity [17] is not mediated by PKC-
oe. 
In contrast to short-term treatments, longer-term (24 h) 
treatments of MCF-7/MDR cells with 2 and 5 μΜ TAM 
inhibited the effects of PMA on PtdEtn hydrolysis by about 
50 and 80%, respectively (Fig. 3). It should be noted that 
longer-term treatments with these concentrations of TAM 
had no significant effects on the cellular level of [14C]PtdEtn, 
reflecting the transient nature of the stimulatory effect of 
TAM on PLD activity. However, 10-15 μΜ concentrations 
of TAM decreased both the cell numbers and the cellular level 
of PtdEtn after treatments for 24 h; for this reason, we have 
not attempted to increase the concentration of TAM above 
5 μΜ. 
A longer-term (24 h) treatment of NIH 3T3 fibroblasts with 
5 μΜ TAM inhibited the stimulatory effect of PMA on 
PtdCho hydrolysis about 50% (Fig. 4A); PMA-induced hy-
drolysis of PtdEtn was less affected (~35% inhibition; Fig. 
4B). Overall, 5 μΜ TAM was a somewhat less effective inhib-
itor of PMA-induced PLD activity in fibroblasts than in 
MCF-7/MDR cells. The same is true when the effects of a 
lower (2 μΜ) concentration TAM are compared in fibroblasts 
and MCF-7/MDR cells (Fig. 4 compared to Fig. 3). 
Recently, Gundimeda et al. [20] reported that longer-term 
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Fig. 4. Effects of longer-term treatments with TAM on PMA-stimu-
lated phospholipid hydrolysis in NIH 3T3 fibroblasts. Fibroblasts 
were labeled with [14C]choline (A) or [14C]ethanolamine (B) for 48 
h, and were untreated (·) or treated with 2 μΜ TAM (▲) or 5 μΜ 
TAM (■) for the last 24 h of the labeling period. Washed cells were 
incubated, in the absence of TAM, with 0-100 nM concentrations 
of PMA for 90 min. The 14C content of PtdCho and PtdEtn was 
228000 and 239000 dpm/well, respectively. Each point represents 
the mean ± S.E.M. of six incubations in two separate experiments 
with the same passage of cells. Similar results were obtained in a 
third experiment performed in quadruplicate. 
Fig. 5. Western blot analysis of PKC-α in TAM-treated MCF-7/ 
MDR cells. MCF-7/MDR cells were untreated (lanes 1, 2) or were 
treated with 5 μΜ TAM for 20 min (lanes 3, 4) or 24 h (lanes 5, 
6). Lane I represents molecular weight standards. Lane II represents 
PKC-α standard from rat brain shown by the arrow. Lanes 1, 3, 5 
were loaded with 35 μg soluble fraction protein and lanes 2, 4, 6 
were loaded with 35 μg of paniculate fraction protein. This experi-
ment was repeated once with similar results. 
treatments of MDA-MB-231 breast carcinoma cells with 
TAM lead to the down-regulation of calcium-dependent 
PKC activity. Our results also indicated that the function of 
PKC-oc as a regulator of PLD activity in MCF-7/MDR cells is 
blocked by extended treatments with TAM. It was of interest 
to see if such TAM-induced reduction in the function of PKC-
oc is due to its physical down-regulation perhaps preceded 
by membrane translocation. However, in MCF-7/MDR cells 
5 μΜ TAM induced neither membrane translocation nor 
down-regulation of PKC-oc after treatments for 20 min or 
24 h (Fig. 5). In other experiments, treatments with 15 and 
25 μΜ TAM for 20 min also failed to induce membrane 
translocation of PKC-oc (data not shown). 
In treated patients the intratumor concentration of TAM 
can reach a level equivalent to 3.4-6.7 μΜ [21]. Here, we have 
shown that chronic treatments with 2-5 μΜ concentrations of 
TAM can cause significant inhibition of PMA-stimulated 
PLD activity particularly in MCF-7/MDR cells. These obser-
vations suggest that the observed inhibition of this important 
regulatory function of PKC-oc may be a clinically relevant 
effect of TAM perhaps contributing to the hitherto unex-
plained beneficial effects of TAM in patients with ER-negative 
tumors [8]. 
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